Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Cellectis (NASDAQ:CLLS – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Profitability
This table compares Amylyx Pharmaceuticals and Cellectis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -52.92% | -48.53% |
| Cellectis | -102.34% | -94.19% | -21.34% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Amylyx Pharmaceuticals and Cellectis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 0 | 7 | 1 | 2.89 |
| Cellectis | 2 | 2 | 2 | 1 | 2.29 |
Amylyx Pharmaceuticals presently has a consensus price target of $40.71, suggesting a potential upside of 38.48%. Cellectis has a consensus price target of $5.46, suggesting a potential upside of 366.67%. Given Cellectis’ higher probable upside, analysts clearly believe Cellectis is more favorable than Amylyx Pharmaceuticals.
Earnings and Valuation
This table compares Amylyx Pharmaceuticals and Cellectis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $87.37 million | 37.49 | -$144.74 million | ($1.43) | -20.56 |
| Cellectis | $56.58 million | 2.08 | -$67.59 million | ($0.65) | -1.80 |
Cellectis has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Amylyx Pharmaceuticals has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.21, suggesting that its stock price is 221% more volatile than the S&P 500.
Institutional & Insider Ownership
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Amylyx Pharmaceuticals beats Cellectis on 7 of the 13 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
